Iterum Therapeutics Future Growth

NasdaqCM:ITRM - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	26	-11	-7	N/A	2
12/31/2025	12	-20	-18	N/A	2
12/31/2024	N/A	-39	-49	N/A	2
12/31/2023	N/A	-38	-39	-39	N/A
9/30/2023	N/A	-31	-31	-31	N/A
6/30/2023	N/A	-56	-26	-26	N/A
3/31/2023	N/A	-51	-25	-25	N/A
12/31/2022	N/A	-44	-19	-18	N/A
9/30/2022	N/A	-44	-17	-17	N/A
6/30/2022	N/A	-11	-16	-16	N/A
3/31/2022	N/A	4	-18	-18	N/A
12/31/2021	N/A	-92	-16	-16	N/A
9/30/2021	N/A	-99	-22	-22	N/A
6/30/2021	N/A	-115	-23	-23	N/A
3/31/2021	N/A	-135	-28	-28	N/A
12/31/2020	N/A	-52	-55	-55	N/A
9/30/2020	N/A	-64	-69	-69	N/A
6/30/2020	N/A	-84	-90	-90	N/A
3/31/2020	N/A	-99	-94	-94	N/A
12/31/2019	0	-103	-82	-82	N/A
9/30/2019	0	-104	-83	-83	N/A
6/30/2019	1	-97	-85	-85	N/A
3/31/2019	1	-85	-79	-79	N/A
12/31/2018	1	-77	-77	-77	N/A
9/30/2018	1	-62	-62	-62	N/A
6/30/2018	1	-45	-40	-40	N/A
3/31/2018	1	-36	-37	-37	N/A
12/31/2017	1	-29	-31	-31	N/A

Analyst Future Growth Forecasts

Revenue vs Market: ITRM is forecast to have no revenue next year.

High Growth Revenue: ITRM is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if ITRM's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Iterum Therapeutics Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Consensus forecasts updated

Price target increased to US$2.00

Consensus revenue estimates increase to US$2.86m

Price target lowered to US$3.33

Recent updates

Insufficient new directors

Iterum Therapeutics plc to Report Q4, 2023 Results on Mar 28, 2024

Iterum Therapeutics plc Announces Positive Topline Results from Its Phase 3 Reassure Clinical Trial of Oral Sulopenem in Un Complicated Urinary Tract Infections

New major risk - Financial position

Iterum Therapeutics plc Announces the Resignation of Mark Chin as Director, Effective December 31, 2023

New major risk - Revenue and earnings growth

Iterum Therapeutics plc to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Share price stability

Iterum Therapeutics plc Announces Completion of Enrollment in its REASSURE Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Iterum Therapeutics plc to Report Q2, 2023 Results on Aug 11, 2023

Iterum Therapeutics plc, Annual General Meeting, May 03, 2023

Iterum Therapeutics plc to Report Q3, 2022 Results on Nov 10, 2022

Iterum Announces First Patient Dosed in Reassure, A Phase 3 Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

Iterum Therapeutics plc Announces Issuance of Allowance for A U.S. Patent Covering Oral Sulopenem

Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Non-GAAP EPS of -$0.03 beats by $0.03

Iterum Therapeutics plc Announces Special Protocol Assessment Agreement with the FDA

Iterum jumps 64% as FDA agrees to Phase 3 trial for UTI candidate

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics plc, Annual General Meeting, Jun 15, 2022

Iterum Therapeutics plc to Report Q4, 2021 Results on Mar 28, 2022

Does Iterum Therapeutics (NASDAQ:ITRM) Have A Healthy Balance Sheet?

Iterum Therapeutics Provides Update from FDA Type A Meeting Regarding Oral Sulopenem

Is Iterum Therapeutics (NASDAQ:ITRM) A Risky Investment?

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Filed Against Iterum Therapeutics plc

Pomerantz Law Firm Announces the Filing of Class Action against Iterum Therapeutics plc and Certain Officers

Despite Risks Around Regulatory Approval, Iterum Therapeutics Rates A Speculative Buy

Iterum Therapeutics plc Receives Letter from the U.S. Food and Drug Administration as Part of Their Ongoing Review of the New Drug Application for sulopenem etzadroxil/probenecid

Independent Director Mohammed Shahzad Malik has left the company

It's Unlikely That The CEO Of Iterum Therapeutics plc (NASDAQ:ITRM) Will See A Huge Pay Rise This Year

Consensus forecasts updated

Iterum Therapeutics plc Provides Update on NDA Review

Is Iterum Therapeutics (NASDAQ:ITRM) Using Debt Sensibly?

Price target increased to US$2.00

Consensus revenue estimates increase to US$2.86m

Independent Director has left the company

Iterum Therapeutics Appoints Beth P. Hecht to Board of Directors

Iterum Therapeutics plc to Report Q4, 2020 Results on Mar 12, 2021

New 90-day high: US$2.27

Have Insiders Been Selling Iterum Therapeutics plc (NASDAQ:ITRM) Shares?

This Insider Has Just Sold Shares In Iterum Therapeutics plc (NASDAQ:ITRM)

Iterum Therapeutics shares slide 13% on raising $10M

Iterum Therapeutics plc Announces Collaboration with Eversana to Support Oral Sulopenem Launch

President recently sold US$148k worth of stock

Iterum Therapeutics plc Announces U.S. FDA Filing Acceptance of New Drug Application for Oral Sulopenem

New 90-day high: US$1.23

Iterum Therapeutics plc Announces Executive Changes

Iterum Therapeutics rises 39% on RA Capital stake disclosure

Iterum Therapeutics files US application for sulopenem in urinary tract infections

Earnings beat expectations

Iterum Therapeutics EPS beats by $0.45

Iterum Therapeutics plc has completed a Follow-on Equity Offering in the amount of $17.385884 million.

New 90-day low: US$0.53

Iterum Therapeutics plc Plans to Proceed with an NDA Submission for sulopenem etzadroxil/probenecid

New 90-day low - US$0.68

Iterum Therapeutics plc has completed a Composite Units Offering in the amount of $6.374 million.

New 90-day low - US$0.98

Price target lowered to US$3.33

Iterum Therapeutics Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies